The FDA approved the oral formulation of Novo Nordisk’s weight‑loss drug Wegovy, marking the first regulatory clearance of an oral GLP‑1 for obesity in years. The approval covers treatment for obesity and carries the same cardiovascular risk‑reduction indication as the injectable version, according to FDA and company statements. Novo Nordisk will launch the pill alongside its established injectable franchise, which could broaden patient access by removing injection barriers and expanding prescriber options. Payers and distributors will now reassess coverage, formularies and dispensing pathways for oral GLP‑1 therapy. Sources: FDA approval notice, Novo Nordisk communications.